Atossa Genetics completes enrollment in phase 2 study of Topical Endoxifen
Atossa Genetics has completed enrollment in its Phase 2 study of Atossa’s proprietary Topical Endoxifen in women with mammographic breast density, or MBD. The primary endpoint is to determine if daily Topical Endoxifen administration results in an individual change in MBD. October 11, 2018